Evidence map›Paper›PMID 28608264›Full record

ArticleCell stress & chaperones2018

The small heat shock protein B8 (HSPB8) efficiently removes aggregating species of dipeptides produced in C9ORF72-related neurodegenerative diseases.

Riccardo Cristofani, Valeria Crippa, Giulia Vezzoli, Paola Rusmini, Mariarita Galbiati, Maria Elena Cicardi, Marco Meroni, Veronica Ferrari, Barbara Tedesco, Margherita Piccolella and 3 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Cell stress & chaperones, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03693781 (Colchicine for Amyotrophic Lateral Sclerosis), which is not on this map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03693781 phase2completednot on this mapstarted 2019, after this paper: background citation

Colchicine for Amyotrophic Lateral Sclerosis: a Phase II, Randomized, Double Blind, Placebo Controlled, Multicenter Clinical Trial

TypeinterventionalSponsorAzienda Ospedaliero-Universitaria di ModenaRan2019 to 2023Enrolled54ConditionsAmyotrophic Lateral SclerosisArmsColchicine 1 MG Oral Tablet, Placebo Oral Tablet
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 95 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Small heat shock proteins and biomolecular condensates.Cellular and molecular life sciences : CMLS · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. ALS' Perfect Storm:Cells · 2024
    Review
  14. Review
  15. iScience · 2023
    Article
  16. Article
  17. Cells · 2023
    Article
  18. Article
  19. Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Riccardo CristofaniSezione di Biomedicina e Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Università degli Studi di Milano, Via Balzaretti 9, 20133, Milan, Italy.
Valeria CrippaSezione di Biomedicina e Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Università degli Studi di Milano, Via Balzaretti 9, 20133, Milan, Italy.
Giulia VezzoliSezione di Biomedicina e Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Università degli Studi di Milano, Via Balzaretti 9, 20133, Milan, Italy.
Paola RusminiSezione di Biomedicina e Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Università degli Studi di Milano, Via Balzaretti 9, 20133, Milan, Italy.
Mariarita GalbiatiSezione di Biomedicina e Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Università degli Studi di Milano, Via Balzaretti 9, 20133, Milan, Italy.
Maria Elena CicardiSezione di Biomedicina e Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Università degli Studi di Milano, Via Balzaretti 9, 20133, Milan, Italy.
Marco MeroniSezione di Biomedicina e Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Università degli Studi di Milano, Via Balzaretti 9, 20133, Milan, Italy.
Veronica FerrariSezione di Biomedicina e Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Università degli Studi di Milano, Via Balzaretti 9, 20133, Milan, Italy.
Barbara TedescoSezione di Biomedicina e Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Università degli Studi di Milano, Via Balzaretti 9, 20133, Milan, Italy.
Margherita PiccolellaSezione di Biomedicina e Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Università degli Studi di Milano, Via Balzaretti 9, 20133, Milan, Italy.
Elio MessiSezione di Biomedicina e Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Università degli Studi di Milano, Via Balzaretti 9, 20133, Milan, Italy.
Serena CarraDipartimento di Scienze Biomediche, Metaboliche e Neuroscienze, Università di Modena e Reggio Emilia, Modena, Italy.
Angelo PolettiSezione di Biomedicina e Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Università degli Studi di Milano, Via Balzaretti 9, 20133, Milan, Italy. angelo.poletti@unimi.it.ORCID 0000-0002-8883-0468
University of Milan · ITUniversity of Modena and Reggio Emilia · ITUniversity of Rome Tor Vergata · IT

Funding

Association Française contre les Myopathies 16406European Molecular Biology Organization 537 - 2015Fondazione Arisla ALS_GranulopathyFondazione Arisla ALS_HSPB8Fondazione AriSLA ALS_GranulopathyFondazione AriSLA ALS_HSPB8Fondazione Cariplo 2014-0686Fondazione regionale per la ricerca biomedica (FRRB), Regione Lombardia TRANS_ALSFondazione Telethon GGP14039Joint Programme Neurodegenerative Disease CureALS n. 643417Joint Programme on Neurodegenerative Diseases Cure_ALS n. 643417Ministero della Salute GR-2011-02347198Ministero dell'Istruzione, dell'Università e della Ricerca PRIN n. 2015LFPNMNUniversità degli studi di Milano piano di sviluppo UNIMI - linea B
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two neurodegenerative diseases in which similar pathogenic mechanisms are involved. Both diseases associate to the high propensity of specific misfolded proteins, like TDP-43 or FUS, to mislocalize and aggregate. This is partly due to their intrinsic biophysical properties and partly as a consequence of failure of the neuronal protein quality control (PQC) system. Several familial ALS/FTD cases are linked to an expansion of a repeated G4C2 hexanucleotide sequence present in the C9ORF72 gene. The G4C2, which localizes in an untranslated region of the C9ORF72 transcript, drives an unconventional repeat-associated ATG-independent translation. This leads to the synthesis of five different dipeptide repeat proteins (DPRs), which are not "classical" misfolded proteins, but generate aberrant aggregation-prone unfolded conformations poorly removed by the PQC system. The DPRs accumulate into p62/SQSTM1 and ubiquitin positive inclusions. Here, we analyzed the biochemical behavior of the five DPRs in immortalized motoneurons. Our data suggest that while the DPRs are mainly processed via autophagy, this system is unable to fully clear their aggregated forms, and thus they tend to accumulate in basal conditions. Overexpression of the small heat shock protein B8 (HSPB8), which facilitates the autophagy-mediated disposal of a large variety of classical misfolded aggregation-prone proteins, significantly decreased the accumulation of most DPR insoluble species. Thus, the induction of HSPB8 might represent a valid approach to decrease DPR-mediated toxicity and maintain motoneuron viability.

Indexed as

Protein AggregatesAnimalsAutophagyC9orf72 ProteinCell Line, TransformedDipeptidesGene SilencingHSP20 Heat-Shock ProteinsMiceMotor NeuronsNeurodegenerative DiseasesProteasome InhibitorsUp-RegulationC9orf72 ProteinDipeptidesHSP20 Heat-Shock ProteinsProteasome InhibitorsProtein AggregatesHSPB8Motor neuron diseasesProtein aggregationProtein clearanceRAN translation

Identifiers

PMID28608264
PMCPMC5741577
OpenAlexW2626717353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.